How to mediate cardioprotection in ischemic hearts--accumulated evidence of basic research should translate to clinical medicine

Cardiovascular Drugs and Therapy
Masafumi Kitakaze

Abstract

Ischemic heart failure is one of the leading causes of death in the western countries and it is a critical issue to overcome ischemic heart diseases for the human health care worldwide. There are several aspects of ischemic heart failure that we need to seriously consider for the conquest of cardiovascular death. First of all, we need to know either causes or pathophysiology of the onset of coronary artery disease, the ischemia/reperfusion injury and post-infarction cardiac remodeling. Secondly, we need to find the potential seeds for the molecular, pharmacological, biomedical or engineering treatment to prevent or attenuate ischemic heart diseases. Thirdly, we need to accelerate translational research and to create the network of clinical trials to grow the novel seeds to the fruitful big trees. Finally, we need to justify these strategies to overcome the ischemic heart diseases and to contribute the world welfare systems after we propose the novel therapy for the prevention and attenuation of ischemic heart diseases. The most strong and essential hypotheses to attenuate the cardiovascular injury in ischemic heart disease for last three decades are ischemic preconditioning/postconditioning. Many investigators have involved in ...Continue Reading

References

Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·E MarbanV P Chacko
Sep 1, 1988·The Journal of Clinical Investigation·M KitakazeE Marban
Feb 1, 1987·Circulation Research·D G Allen, C H Orchard
Dec 1, 1974·The Journal of Clinical Investigation·R A KlonerR B Jennings
Oct 1, 1994·The Journal of Clinical Investigation·R A GottliebR L Engler
Nov 1, 1996·Cardiovascular Research·K MubagwaW Flameng
Sep 4, 1999·Japanese Circulation Journal·M KitakazeM Hori
Oct 31, 2001·Cardiovascular Research·R SchulzG Heusch
Jul 16, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Zhi-Qing ZhaoJakob Vinten-Johansen
Nov 26, 2004·American Journal of Physiology. Heart and Circulatory Physiology·He-Ying SunZhi-Qing Zhao
May 6, 2008·Cardiovascular Research·Derek J Hausenloy, Derek M Yellon
Aug 2, 2008·The New England Journal of Medicine·Christophe PiotMichel Ovize
May 22, 2010·Cardiovascular Drugs and Therapy·Tetsuji Miura, Masaya Tanno
May 25, 2010·Cardiovascular Drugs and Therapy·Derek J Hausenloy, Derek M Yellon
May 28, 2010·Cardiovascular Drugs and Therapy·Xiulan YangJames M Downey
Jun 10, 2010·Cardiovascular Drugs and Therapy·Zhi-Qing Zhao
Jul 1, 2010·Cardiovascular Drugs and Therapy·Fabrice IvanesMichel Ovize
Aug 7, 2010·Cardiovascular Drugs and Therapy·Masanori Asakura, Masafumi Kitakaze

❮ Previous
Next ❯

Citations

Jan 18, 2011·American Journal of Respiratory Cell and Molecular Biology·Martin UrnerBeatrice Beck-Schimmer
May 17, 2011·Annals of Medicine·Alessandro PingitoreGiorgio Iervasi
May 25, 2011·Circulation. Heart Failure·Sachiko KankiRichard T Lee
Aug 23, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Shoji SanadaMasafumi Kitakaze
Dec 19, 2019·Cardiovascular Drugs and Therapy·Willem J Remme

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.